Autoimmune Encephalitis antibody-negative disease
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
|
Autoimmune Encephalitis Microchapters |
|
Differentiating Autoimmune Encephalitis from Other Conditions |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune Encephalitis On the Web |
Overview
Antibody-negative autoimmune encephalitis describes a clinically supported autoimmune encephalitis syndrome in which recognized neural antibodies have not been identified. The designation requires appropriate testing of serum and cerebrospinal fluid (CSF), objective assessment, and exclusion of competing diagnoses. A negative antibody panel alone does not establish autoimmune encephalitis.[1]
The term seronegative is sometimes used, but absence of antibodies in serum alone is insufficient. Two important categories are probable antibody-negative autoimmune encephalitis and definite autoimmune limbic encephalitis meeting antibody-independent criteria. Patients meeting only possible criteria require further evaluation.[2]
Why Antibody Tests May Be Negative
- The tested panel may omit the relevant antigen, or the assay may have insufficient sensitivity.
- Testing only one specimen type may miss an antibody detectable in the other.
- An antibody against an antigen not yet characterized may be present.
- Some immune-mediated inflammation may involve mechanisms other than a recognized circulating neural antibody. These possibilities do not prove an autoimmune cause in an individual patient.[1][3]
Specialist laboratories can combine tissue-based and cell-based methods. Review of the clinical phenotype and laboratory methods is preferable to assuming that a negative commercial panel excludes every neural antibody.[1]
Clinical Presentation
Presentations may include rapidly progressive memory impairment, confusion, psychiatric changes, seizures, movement abnormalities, or reduced consciousness. These manifestations overlap substantially with infectious, metabolic, neoplastic, and other disorders; none independently identifies antibody-negative autoimmune encephalitis.[3]
Diagnostic Criteria
Probable antibody-negative autoimmune encephalitis in adults
The 2016 consensus framework requires all four of the following:[4]
- Memory, mental-status, or psychiatric disturbance progressing over less than 3 months.
- Exclusion of a better-defined autoimmune encephalitis syndrome, such as typical limbic encephalitis, Bickerstaff brainstem encephalitis, or acute disseminated encephalomyelitis.
- Absence of well-characterized neural autoantibodies in both serum and CSF, with at least two of three supporting evidence categories:
- Magnetic resonance imaging (MRI) abnormalities suggestive of autoimmune encephalitis.
- CSF pleocytosis, CSF-restricted oligoclonal bands, or an elevated CSF immunoglobulin G (IgG) index.
- Brain biopsy demonstrating inflammation while excluding another explanation, such as a tumor.
- Reasonable exclusion of alternative causes.
Multiple abnormal CSF measurements count as one evidence category. Electroencephalography (EEG) abnormalities do not constitute an additional category in this definition. Inflammatory brain pathology is not specific for autoimmunity, and biopsy is not routinely required.[4][2]
Antibody-negative definite autoimmune limbic encephalitis
Definite autoimmune limbic encephalitis can be diagnosed without detectable antibodies when all four requirements are met:[5]
- A limbic syndrome developing over less than 3 months, involving memory disturbance, seizures, or psychiatric symptoms.
- Bilateral medial temporal abnormalities on T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI, largely restricted to those regions.
- CSF white blood cell count >5/mm³ or temporal epileptiform/slow-wave EEG activity.
- Reasonable exclusion of other causes.
Unilateral abnormalities or temporal EEG changes alone do not satisfy this antibody-independent pathway. If one of the first three requirements is absent, a relevant neural antibody is needed to establish definite autoimmune limbic encephalitis under this framework.[5]
Diagnostic Evaluation
| Component | Purpose and interpretation |
|---|---|
| Paired serum and CSF antibody testing | Review panel coverage, specimen selection, and assay methodology. Consider specialist tissue-based testing and additional cell-based assays when suspicion persists.[1] |
| CSF examination | Assess cell count, protein, glucose, oligoclonal bands, and IgG index, together with infection testing appropriate to the presentation.[2] |
| Brain MRI | Evaluate the distribution and evolution of abnormalities and investigate structural mimics. Repeat imaging may help when initial findings are normal or the subsequent course is atypical.[2] |
| EEG | Detect seizures, non-convulsive status epilepticus, and cerebral dysfunction. An abnormal EEG does not by itself establish autoimmune inflammation.[4] |
| Selected additional studies | Fluorodeoxyglucose positron emission tomography (FDG-PET) may provide complementary evidence, but its abnormalities are nonspecific. Biopsy is reserved for selected cases, particularly when another pathology is suspected.[2] |
The 2026 United Kingdom (UK) Joint Societies guideline recommends considering repeat antibody testing when a core autoimmune encephalitis phenotype persists despite negative initial serum and CSF results. Diagnostic uncertainty warrants discussion with a specialist center about additional assays.[3]
Exclusion of Mimics
Important alternatives include:
- Infection, particularly herpes simplex virus (HSV) encephalitis.
- Seizures or status epilepticus with secondary cognitive or imaging changes.
- Toxic, medication-related, or metabolic encephalopathy.
- Brain tumors and central nervous system lymphoma.
- Other inflammatory or demyelinating disorders.
- Neurodegenerative, genetic, or mitochondrial disease.
- Primary psychiatric illness when neurological and inflammatory evidence is absent or inconsistent.[1][6]
An early negative HSV polymerase chain reaction (PCR) test may require repetition when clinical suspicion remains high. Infection and autoimmunity should be investigated in parallel.[3]
Children and Adolescents
The provisional pediatric framework differs from the adult criteria. Probable antibody-negative pediatric autoimmune encephalitis requires a compatible clinical presentation, exclusion of alternatives, negative neural antibody testing, and at least one objective investigation showing neuroinflammation. Clinical assessment includes acquired cognitive or developmental change, movement disorders, psychiatric symptoms, seizures, and other neurological deficits.[6]
EEG abnormalities may support encephalopathy but do not count as evidence of neuroinflammation in this pediatric framework. If neither relevant antibodies nor objective inflammatory evidence emerge, the diagnosis requires reconsideration. Developmental history and genetic or metabolic alternatives deserve particular attention.[6]
Treatment Principles
Treatment decisions depend on diagnostic confidence, severity, and exclusion of major alternatives. Negative antibody results should not automatically prevent treatment of a well-supported syndrome. Conversely, patients meeting only possible criteria require specialist assessment before an immunotherapy trial.[2]
- First-line immunotherapy generally involves corticosteroids, intravenous immunoglobulin (IVIG), plasma exchange, or a combination selected for the clinical circumstances.
- Measure response using objective findings such as cognitive assessment, seizure frequency, neurological examination, and functional ability.
- With inadequate response, reassess the diagnosis before escalating immunosuppression. The Canadian consensus favors rituximab over cyclophosphamide for second-line treatment of supported antibody-negative disease, with specialist input.[2]
Improvement with corticosteroids alone does not confirm autoimmune causation. Treatment for seizures and other symptoms, rehabilitation, and monitoring for immunotherapy complications remain integral to care.[4][7]
Tumor Screening
An absent neural antibody does not eliminate the possibility of an associated neoplasm. The Canadian consensus recommends initial tumor screening in adult autoimmune encephalitis. The optimal surveillance schedule for antibody-negative disease is uncertain; repeat screening is individualized, especially with limbic encephalitis, refractory or relapsing disease, or substantial cancer risk.[2]
Follow-up and Prognosis
Recovery and residual disability vary, and evidence specific to antibody-negative disease remains limited. Follow-up should assess cognition, mood, sleep, fatigue, seizures, daily functioning, and rehabilitation needs. Long-term immunotherapy is individualized according to diagnostic confidence, disease activity, relapses, and treatment risks.[7]
New deterioration warrants reassessment for relapse, infection, seizures, medication effects, and alternative diagnoses. Residual symptom fluctuations do not by themselves demonstrate renewed inflammation. Serial clinical findings and appropriately selected repeat investigations help determine whether the original diagnosis remains supported.[7][1]
Related Microchapters
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Dalmau J, Graus F (2023). "Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease". The Lancet Neurology. 22 (6): 529–540. doi:10.1016/S1474-4422(23)00083-2. PMID 37210100 Check
|pmid=value (help). - ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Hahn C, Budhram A, Alikhani K; et al. (2024). "Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults". Canadian Journal of Neurological Sciences. 51 (6): 734–754. doi:10.1017/cjn.2024.16. PMID 38312020 Check
|pmid=value (help). - ↑ 3.0 3.1 3.2 3.3 Michael BD, Huang Y, McKeever S; et al. (2026). "Management of suspected infectious and autoimmune encephalitis in adults – National Guidelines from the United Kingdom Joint Societies". Journal of Infection: 106873. doi:10.1016/j.jinf.2026.106873. PMID 42863638 Check
|pmid=value (help). - ↑ 4.0 4.1 4.2 4.3 Graus F, Titulaer MJ, Balu R; et al. (2016). "A clinical approach to diagnosis of autoimmune encephalitis". The Lancet Neurology. 15 (4): 391–404. doi:10.1016/S1474-4422(15)00401-9. PMID 26906964.
- ↑ 5.0 5.1 Budhram A, Leung A, Nicolle MW, Burneo JG (2019). "Diagnosing autoimmune limbic encephalitis". CMAJ. 191 (19): E529–E534. doi:10.1503/cmaj.181548. PMID 31085562.
- ↑ 6.0 6.1 6.2 Cellucci T, Van Mater H, Graus F; et al. (2020). "Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient". Neurology: Neuroimmunology & Neuroinflammation. 7 (2): e663. doi:10.1212/NXI.0000000000000663. PMID 31953309.
- ↑ 7.0 7.1 7.2 Abboud H, Probasco J, Irani SR; et al. (2021). "Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management". Journal of Neurology, Neurosurgery & Psychiatry. 92 (8): 897–907. doi:10.1136/jnnp-2020-325302. PMID 33649021 Check
|pmid=value (help).